Pathogen: SARS-CoV-2

Geismar

United Kingdom
|
2020-2022
  • General population
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Community
  • Household
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

SIREN Winter Pressures sub-study

United Kingdom
|
2022-2023
  • Adults (18-64 years)
  • Elderly (≥65 years)
  • Healthcare workers
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

FIDO

United Kingdom Ireland
|
2022-2023
  • General population
  • Infants (<1 year)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

Santus

Italy
|
2022-2023
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • Emergency department
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

Maglione

Italy
|
2023-2025
  • General population
  • Infants (<1 year)
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19
  • Pharmacological intervention
  • Monoclonal antibodies
  • Nirsevimab

PAPI Study

Germany
|
2021
  • General population
  • Infants (<1 year)
  • Children (1-11 years)
  • Hospital
  • Primary care
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Human metapneumovirus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19
  • Human metapneumovirus infection

BUCOSS RSV 60+

Germany
|
2022-2025
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Primary care
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

RESP-VIR

Italy
|
2025-2026
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Infants (<1 year)
  • Adolescents (12-17 years)
  • Children (1-11 years)
  • Hospital
  • Non-hospital health centre
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Adenovirus
  • Metapneumovirus
  • Parainfluenza Virus
  • Rhinovirus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19
  • Adenovirus infection
  • Metapneumovirus infection
  • Parainfluenza virus infection
  • Rhinovirus infection

MIViral

Switzerland
|
2023-2024
  • Adults (18-64 years)
  • General population
  • Elderly (≥65 years)
  • Hospital
  • SARS-CoV-2
  • Respiratory syncytial virus
  • Influenza virus
  • Respiratory syncytial virus infection
  • Influenza
  • COVID-19

STIMULATE-ICP

United Kingdom of Great Britain and Northern Ireland
|
2022
  • Adults (18-64 years)
  • General population
  • Community
  • SARS-CoV-2
  • Post-COVID-19
  • Colchicine
  • Antihistamines
  • Rivaroxaban

RECLAIM

The Netherlands
|
2025
  • Adults (18-64 years)
  • Outpatient clinic
  • Community
  • Primary care
  • SARS-CoV-2
  • Post-COVID-19
  • Pharmacological intervention
  • Immunomodulator
  • Colchicine
  • Metformin

COVID COHORT – SPAIN

Spain
|
2020-2025
  • Adults (18-64 years)
  • General population
  • Hospital
  • SARS-CoV-2
  • Acute COVID-19
  • Blood sample
  • PBMC
  • Whole blood